{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:53:00Z","timestamp":1793159580634,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography A"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.chroma.2024.465176","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T19:01:59Z","timestamp":1721329319000},"page":"465176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["A multianalyte LC-MS\/MS method for accurate quantification of Nitrosamines in Olmesartan tablets"],"prefix":"10.1016","volume":"1732","author":[{"given":"Namdev","family":"Pawar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7387-1718","authenticated-orcid":false,"given":"Aparna","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amisha","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.chroma.2024.465176_bib0001","first-page":"20","article-title":"N-Nitrosodimethylamine (NDMA) in food and beverages: a comparison in context to drinking water","author":"Chowdhury","year":"2014","journal-title":"Hum. Ecol. Risk Assess."},{"key":"10.1016\/j.chroma.2024.465176_bib0002","unstructured":"European Medicines Agency (2020); Nitrosamine impurities in human medicinal products; EMEA\/H\/A-5(3)\/1490 https:\/\/www.ema.europa.eu\/en\/documents\/referral\/nitrosamines-emea-h-a53-1490-assessment-report_en.pdf."},{"key":"10.1016\/j.chroma.2024.465176_bib0003","unstructured":"IPA Guidance on Nitrosamines. (2022). Published by Indian Pharmaceutical Alliance available at: https:\/\/www.ipa-india.org\/wp-content\/uploads\/2023\/07\/guideline-05072023c.pdf."},{"key":"10.1016\/j.chroma.2024.465176_bib0004","series-title":"U.S. Food and Drug Administration","year":"2021"},{"issue":"2","key":"10.1016\/j.chroma.2024.465176_bib0005","first-page":"2020","article-title":"Understanding the molecular-pharmaceutical basis of Sartan recalls focusing on valsartan","author":"Ray","year":"2021","journal-title":"Glob. Cardiol. Sci. Practice"},{"key":"#cr-split#-10.1016\/j.chroma.2024.465176_bib0006.1","unstructured":"European Medicines Agency (2020)"},{"key":"#cr-split#-10.1016\/j.chroma.2024.465176_bib0006.2","unstructured":"Impact of the Article 5(3) scientific opinion on nitrosamines in human medicinal products on the Opinion adopted pursuant to Article 31 of Directive 2001\/83\/EC for angiotensin-II-receptor antagonists (sartans) containing a tetrazole group (candesartan, irbesartan, losartan, olmesartan, valsartan)"},{"key":"#cr-split#-10.1016\/j.chroma.2024.465176_bib0006.3","unstructured":"European Medicines Agency (2020); Impact of the Article 5"},{"key":"#cr-split#-10.1016\/j.chroma.2024.465176_bib0006.4","unstructured":"(3) scientific opinion on nitrosamines in human medicinal products on the Opinion adopted pursuant to Article 31 of Directive 2001\/83\/EC for angiotensin-II-receptor antagonists (sartans) containing a tetrazole group (candesartan, irbesartan, losartan, olmesartan, valsartan); EMEA\/H\/A-31\/1471 https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report-impact-article-53-scientific-opinion-nitrosamines_en.pdf."},{"key":"10.1016\/j.chroma.2024.465176_bib0007","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1365\/s10337-007-0304-9","article-title":"Simultaneous HPLC analysis of olmesartan and hydrochlorothiazide in combined tablets and in vitro dissolution studies","volume":"66","author":"Sagirli","year":"2007","journal-title":"Chromatographia"},{"key":"10.1016\/j.chroma.2024.465176_bib0008","first-page":"189","article-title":"A validated reversed phase HPLC-method for the determination of olmesartan medoxomil in combination with hydrochlorothiazide","volume":"17","author":"Birajdar","year":"2009","journal-title":"Saudi Pharmaceutic. J."},{"key":"10.1016\/j.chroma.2024.465176_bib0009","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1365\/s10337-009-1094-z","article-title":"RP-LC and HPTLC methods for the determination of olmesartan Medoxomil and hydrochlorothiazide in combined tablet dosage forms","volume":"69","author":"Bari","year":"2009","journal-title":"Chromatographia"},{"key":"10.1016\/j.chroma.2024.465176_bib0010","first-page":"266","article-title":"Development and validation of RP-HPLC method for the simulteneous estimation of olmesartan medoxomil and chlorthalidone in tablet dosage form","volume":"7","author":"Sawale","year":"2015","journal-title":"Int. J. Pharm. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.chroma.2024.465176_bib0011","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2478\/v10007-010-0010-2","article-title":"RP-HPLC-DAD method for determination of olmesartan medoxomil in bulk and tablets exposed to forced conditions","volume":"60","author":"Sharma","year":"2010","journal-title":"Acta Pharmaceutica"},{"issue":"8","key":"10.1016\/j.chroma.2024.465176_bib0012","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/chromsci\/bms067","article-title":"Stability-indicating method for simultaneous estimation of olmesartan medoxomile, amlodipine besylate and hydrochlorothiazide by RP-HPLC in tablet dosage form","volume":"50","author":"Jain","year":"2012","journal-title":"J. Chromatogr. Sci."},{"issue":"7","key":"10.1016\/j.chroma.2024.465176_bib0013","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/chromsci\/48.7.601","article-title":"Stability indicating LC method for the simultaneous determination of amlodipine and olmesartan in dosage form","volume":"48","author":"Patil","year":"2010","journal-title":"J. Chromatogr. Sci."},{"issue":"1\u20132","key":"10.1016\/j.chroma.2024.465176_bib0014","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jchromb.2007.05.049","article-title":"Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry","volume":"856","author":"Liu","year":"2007","journal-title":"J. Chromatogr. B: Anal. Technol. Biomed. Life Sci."},{"issue":"12","key":"10.1016\/j.chroma.2024.465176_bib0015","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/bmc.1447","article-title":"Development and validation of an LC-ESI-MS\/MS method for simultaneous quantitation of olmesartan and pioglitazone in rat plasma and its pharmacokinetic application","volume":"24","author":"Sengupta","year":"2010","journal-title":"Biomed. Chromatogr."},{"issue":"9\u201310","key":"10.1016\/j.chroma.2024.465176_bib0016","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jchromb.2010.01.009","article-title":"Simultaneous quantitative determination of olmesartan and hydrochlorothiazide in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry","volume":"878","author":"Liu","year":"2010","journal-title":"J. Chromatogr. B: Anal. Technol. Biomed. Life Sci."},{"issue":"1\u20132","key":"10.1016\/j.chroma.2024.465176_bib0017","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1365\/s10337-007-0453-x","article-title":"LC-MS-MS determination of olmesartan in human plasma","volume":"67","author":"Vaidya","year":"2008","journal-title":"Chromatographia"},{"key":"10.1016\/j.chroma.2024.465176_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2020.104757","article-title":"Sequential liquid-liquid extraction coupled to LC-MS\/MS for simultaneous determination of amlodipine, olmesartan and hydrochlorothiazide in plasma samples: application to pharmacokinetic studies","volume":"155","author":"Elkady","year":"2020","journal-title":"Microchem. J."},{"issue":"20","key":"10.1016\/j.chroma.2024.465176_bib0019","first-page":"23","article-title":"Development of a sensitive screening method for simultaneous determination of nine genotoxic nitrosamines in active pharmaceutical ingredients by GC-MS","author":"Witkowska","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.chroma.2024.465176_bib0020","doi-asserted-by":"crossref","DOI":"10.22159\/ajpcr.2020.v13i12.39052","article-title":"In Vitro analytical evaluation of nitrosamine \u2013 a carcinogenic impurities in olmesartan Medoximil By GC MS\/MS method","author":"Saradhi","year":"2020","journal-title":"Asian J. Pharmaceutic. Clin. Res."},{"issue":"6\u2013s","key":"10.1016\/j.chroma.2024.465176_bib0021","article-title":"Cost effective accurate and precise analytical method development of content estimation of N-Nitrosodimethyl Amine and N-Nitrosodiethyl amine in olmesartan Medoxomil by GC-MS","volume":"10","author":"Venkatesan","year":"2020","journal-title":"J. Drug Deliv. Therapeutic."},{"key":"10.1016\/j.chroma.2024.465176_bib0022","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jpba.2018.11.010","article-title":"NDMA impurity in valsartan and other pharmaceutical products: analytical methods for the determination of N-nitrosamines","volume":"164","author":"Parr","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.chroma.2024.465176_bib0023","unstructured":"U.S. Food & Drug Admnistration (FDA) (2019). Liquid chromatography-high resolution mass Spectrometry (LC-HRMS) method for the determination of six nitrosamine impurities in ARB drugs. Accessed August 2023. Available at: https:\/\/www.fda.gov\/media\/125478\/download."},{"key":"10.1016\/j.chroma.2024.465176_bib0024","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1039\/C4AY02967D","article-title":"Analysis of nine N-nitrosamines using liquid chromatography-accurate mass high resolution-mass spectrometry on a Q-Exactive instrument \u2020","volume":"7","author":"Djintchui Ngongang","year":"2015","journal-title":"Anal. Methods"},{"issue":"2","key":"10.1016\/j.chroma.2024.465176_bib0025","doi-asserted-by":"crossref","first-page":"292","DOI":"10.38212\/2224-6614.1063","article-title":"A multi-analyte LC-MS\/MS method for screening and quantification of nitrosamines in sartans","volume":"28","author":"Chang","year":"2020","journal-title":"J. Food Drug Anal."},{"key":"10.1016\/j.chroma.2024.465176_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2022.107402","article-title":"Development of an analytical method for the determination and quantification of n-nitrosodimethylamine in olmesartan by HPLC-MS\/MS","volume":"179","author":"Gonz\u00e1lez","year":"2022","journal-title":"Microchem. J."},{"issue":"21","key":"10.1016\/j.chroma.2024.465176_bib0027","first-page":"27","article-title":"Determination of genotoxic impurity N-Nitroso-N-methyl-4-aminobutyric acid in four Sartan substances through using liquid chromatography\u2013tandem mass spectrometry","author":"Xie","year":"2022","journal-title":"Molecules."},{"issue":"2","key":"10.1016\/j.chroma.2024.465176_bib0028","doi-asserted-by":"crossref","DOI":"10.1093\/chromsci\/bmac059","article-title":"A Multi-Analyte LC-MS\/MS Method for Determination and Quantification of Six Nitrosamine Impurities in Sartans like Azilsartan, Valsartan, Telmisartan, Olmesartan, Losartan and Irbesartan","volume":"62","author":"Gopireddy","year":"2024","journal-title":"J. Chromatogr. Sci."},{"issue":"5","key":"10.1016\/j.chroma.2024.465176_bib0029","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.xphs.2023.01.005","article-title":"Investigation of carcinogenic impurities of N-Nitrosamines in Sartan pharmaceutical products marketed in Brazil: development and validation of method based on high-performance liquid chromatography-tandem mass spectrometry","volume":"112","author":"Monteiro","year":"2023","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.chroma.2024.465176_bib0030","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.xphs.2022.12.005","article-title":"Rapid quantitation of four nitrosamine impurities in angiotensin receptor blocker drug substances","volume":"112","author":"Zhang","year":"2023","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.chroma.2024.465176_bib0031","first-page":"112","article-title":"Thymol-based hydrophobic deep eutectic solvents as a green approach for screening polar nitrosamines in sartans pharmaceutical products by ultrasound-assisted dispersive liquid-liquid microextraction combined with HPLC-DAD","author":"Novotny","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.chroma.2024.465176_bib0032","article-title":"An analytical method for determining N -Nitrosodimethylamine and N -Nitrosodiethylamine contamination in irbesartan, olmesartan and metformin by UPLC-APCI-MS\/MS in tablet dosage form","author":"Deeb","year":"2023","journal-title":"J. Chromatogr. Sci"},{"key":"10.1016\/j.chroma.2024.465176_bib0033","unstructured":"ICH - Validation of analytical procedures: text and methodology Q2(R2) 2022. International council on harmonisation of technical requirements for registration of pharmaceuticals for human use. Available at: https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q2-R2_Document_Step2_Guideline_2022_0324.pdf."},{"key":"10.1016\/j.chroma.2024.465176_bib0034","article-title":"Mitigating matrix effects for LC-MS\/MS quantification of nitrosamine impurities in rifampin and rifapentine","volume":"3","author":"Li","year":"2024","journal-title":"J. Pharmaceutic. Biomed. Anal. Open"}],"container-title":["Journal of Chromatography A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021967324005508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021967324005508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T16:11:13Z","timestamp":1724083873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021967324005508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":37,"alternative-id":["S0021967324005508"],"URL":"https:\/\/doi.org\/10.1016\/j.chroma.2024.465176","relation":{},"ISSN":["0021-9673"],"issn-type":[{"value":"0021-9673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multianalyte LC-MS\/MS method for accurate quantification of Nitrosamines in Olmesartan tablets","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography A","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chroma.2024.465176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"465176"}}